Apyx Medical Beheer
Beheer criteriumcontroles 3/4
De CEO Apyx Medical is Charlie Goodwin, benoemd in Dec2017, heeft een ambtstermijn van 6.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.26M, bestaande uit 38.2% salaris en 61.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.26% van de aandelen van het bedrijf, ter waarde $ 105.30K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 6.8 jaar.
Belangrijke informatie
Charlie Goodwin
Algemeen directeur
US$1.3m
Totale compensatie
| Percentage CEO-salaris | 38.2% |
| Dienstverband CEO | 6.9yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 5.8yrs |
| Gemiddelde ambtstermijn bestuur | 6.8yrs |
Recente managementupdates
Recent updates
Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Sep 14
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 07We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Aug 01Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Jun 19Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M
Aug 11Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin
Jul 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$1m | US$483k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$15m |
| Jun 30 2023 | n/a | n/a | -US$16m |
| Mar 31 2023 | n/a | n/a | -US$21m |
| Dec 31 2022 | US$2m | US$483k | -US$23m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$2m | US$450k | -US$15m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$2m | US$450k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$16m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$2m | US$450k | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$15m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$1m | US$400k | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$12m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$2m | US$15k | -US$14m |
Compensatie versus markt: De totale vergoeding ($USD 1.26M ) Charlie } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).
Compensatie versus inkomsten: De vergoeding van Charlie is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Charlie Goodwin (58 yo)
6.9yrs
Tenure
US$1,261,470
Compensatie
Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.9yrs | US$1.26m | 0.26% $ 105.3k | |
| CFO, Treasurer & Secretary | less than a year | US$445.95k | 0.023% $ 9.2k | |
| Senior Vice President | 12.8yrs | US$538.31k | 1.32% $ 534.1k | |
| Executive Vice President | 5.8yrs | US$746.27k | 0% $ 0 | |
| Executive Chairman | less than a year | geen gegevens | 5.04% $ 2.0m |
5.8yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van APYX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.9yrs | US$1.26m | 0.26% $ 105.3k | |
| Executive Chairman | less than a year | geen gegevens | 5.04% $ 2.0m | |
| Independent Director | 13.7yrs | US$114.06k | 0.079% $ 32.2k | |
| Lead Independent Director | 13.7yrs | US$162.56k | 0.12% $ 50.2k | |
| Member of Medical Advisory Board | 5.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | US$9.30k | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Vice-Chairman of the Board | 10.3yrs | US$144.06k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$116.56k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$106.56k | 0.22% $ 90.3k | |
| Member of Medical Advisory Board | 7.8yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 6.5yrs | geen gegevens | geen gegevens |
6.8yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van APYX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).